Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia

Fanconi Anemia Clinical Trial

Official title:

Dose-Finding Study for Cyclophosphamide as Conditioning Regimens for Bone Marrow Transplantation From Related Donors in Patients With Fanconi Anemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00317876
• Other study ID #: 1288.00
• Secondary ID: FHCRC-1288.00CDR
• Status: Completed
• Phase: Phase 1
• First received: April 24, 2006
• Last updated: April 18, 2012
• Start date: June 1998

Study information

• Verified date: April 2012
• Source: Fred Hutchinson Cancer Research Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide, before a donor bone marrow transplant helps stop the growth of abnormal cells. It also stops the patient's immune system from rejecting the donor's bone marrow. The donated bone marrow stem cells may replace the patient's immune system and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and methotrexate before or after transplant may stop this from happening.

PURPOSE: This phase I trial is studying the side effects and best dose of cyclophosphamide in treating patients who are undergoing a donor bone marrow transplant for Fanconi's anemia.

Description:

OBJECTIVES:

• Decrease the conditioning-related toxicity of cyclophosphamide without decreasing the engraftment rate to < 90% in patients undergoing allogeneic bone marrow transplantation for Fanconi's anemia.

OUTLINE: This is a multicenter, dose-finding study of cyclophosphamide.

• Nonmyeloablative conditioning regimen: Patients receive cyclophosphamide IV on days -5 to -2.

Cohorts of 5-10 patients receive decreasing doses of cyclophosphamide until the optimal dose (OD) is determined. The OD is defined as the dose at which ≥ 4 of 5 patients achieve engraftment and < 1 of 10 patients experiences dose-limiting toxicity.

• Allogeneic bone marrow transplantation (BMT): Patients undergo allogeneic BMT on day 0.

• Graft-vs-host-disease (GVHD) prophylaxis: Patients receive cyclosporine orally or IV twice daily beginning on day -1 and continuing until day 49, followed by a taper on days 50-180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

After completion of study treatment, patients are followed periodically for 5 years.

PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. primary completion date: July 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of Fanconi's anemia by chromosome fragility with a diepoxybutane (DEB) or mitomycin C test

• Hemoglobin = 8.0 g/dL, absolute granulocyte count = 1,000/mm^3, or platelet count = 50,000/mm^3

• No refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute leukemia

• HLA-identical related donor available

PATIENT CHARACTERISTICS:

• Glomerular filtration rate = 30% predicted for age

• No liver disease (e.g., active hepatitis or moderate to severe portal fibrosis/cirrhosis by biopsy)

• No symptomatic cardiac insufficiency or symptomatic arrhythmia

• No other diseases that would severely limit the probability of survival

• No HIV seropositivity

• Not pregnant or nursing

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• Not specified

Study Design

Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Anemia
• Fanconi Anemia
• Fanconi Syndrome

Intervention

Drug:
• cyclophosphamide

• cyclosporine

• methotrexate

Procedure:
• allogeneic bone marrow transplantation

• nonmyeloablative allogeneic hematopoietic stem cell transplantation

Locations

Country	Name	City	State
Brazil	Universidade Federal do Parana	Curitiba	Parana
United States	Fred Hutchinson Cancer Research Center	Seattle	Washington
United States	Seattle Cancer Care Alliance	Seattle	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Fred Hutchinson Cancer Research Center	National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Conditioning-related toxicity		100 days post-transplant	Yes
Primary	Graft rejection		100 days post-transplant	No